Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Hyperphosphatemia is a significant risk factor for cardiac mortality in end-stage renal disease (ESRD) patients on hemodialysis (HD).
• Current phosphate binders achieve target serum phosphorus levels in only half of treated ESRD patients, necessitating novel therapeutic strategies.
• Salivary phosphate secretion in ESRD patients is not well-established, despite the potential contribution of saliva to overall phosphate balance.

Purpose of the Study:

• To investigate and compare salivary phosphate secretion levels in hemodialysis patients versus healthy controls.
• To explore the relationship between salivary phosphate, serum phosphate, and other relevant biochemical markers in ESRD patients.

Main Methods:

• Salivary phosphate and calcium levels were measured in 68 HD patients and 30 healthy subjects.
• Serum phosphate, calcium, and parathyroid hormone (PTH) levels were also assessed.
• Salivary function was confirmed as normal in both groups using Saxon's test.

Main Results:

• Hemodialysis patients exhibited significantly elevated salivary phosphorus concentrations compared to healthy controls (30.35 mg/dl vs. 12.1 mg/dl, p < 0.0001).
• Salivary phosphorus levels demonstrated a strong positive correlation with serum phosphorus levels (p < 0.0001).
• Serum phosphorus was identified as the sole significant predictor of salivary phosphorus levels via multiple regression analysis (p < 0.0001).

Conclusions:

• The increased salivary phosphate secretion in ESRD patients may represent a compensatory mechanism for renal failure.
• However, reabsorption of this elevated salivary phosphate could exacerbate hyperphosphatemia.
• Targeting salivary phosphate for binding presents a potential adjunctive therapeutic approach for managing hyperphosphatemia in ESRD.